Assessing the accuracy of
68Ga-PSMA PET/CT
MRI
cancer
prostate
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
17
01
2020
accepted:
22
06
2021
pubmed:
13
7
2021
medline:
6
4
2022
entrez:
12
7
2021
Statut:
ppublish
Résumé
Prostate cancer diagnosis is shifting towards a minimally invasive approach, maintaining accuracy and efficacy while reducing morbidity. We aimed to assess if PSMA-Ga68 PET/CT can accurately grade and localise prostatic malignancy using objective methods, compared with pathology and MRI. Retrospective analysis on 114 consecutive patients undergoing staging PSMA PET/CT scans over 12 months was carried out. The SUVmax and site of highest PSMA activity within the prostate gland were recorded. Pathology/biopsy review assessed maximum Gleason score (and location). MRI analysis assessed the highest PIRADS score and location. The grade, location and size of malignant tissue on biopsy, and PSA, were correlated with the SUVmax and the PIRADS score. SUVmax was significantly elevated in cases with PSA ≥10 (P = 0.003) and Gleason score ≥8 (P = 0.0002). SUVmax demonstrated equivalent sensitivity to MRI-PIRADS in predicting Gleason ≥8 disease, with higher specificity when tested under a high-specificity regime (SUVmax ≥10, PIRADS = 5, P = 0.002). Furthermore, the region of highest SUVmax was superior to MRI-PIRADS for localising the highest grade tumour region, correctly identifying 71% of highest grade regions compared to 54% with MRI (P = 0.015). PSMA PET/CT is as effective as MRI in identifying high-grade prostate malignancy. Our findings also support previous studies in showing a significant relationship between SUVmax and Gleason grade. These benefits, along with the known advantage in identifying distant metastases and the reduced cost, further support the argument that PSMA PET/CT should be offered as an initial investigation in the workup of prostate cancer.
Identifiants
pubmed: 34250746
doi: 10.1111/1754-9485.13284
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-323Informations de copyright
© 2021 The Royal Australian and New Zealand College of Radiologists.
Références
Cancer data in Australia, Australian Institute of Health and Welfare, 18/12/18. [Accessed 11/4/19.] Available from URL: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/rankings
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29. Jan 7. Erratum in: CA Cancer J Clin. 2014 Sep-Oct;64(5):364. PMID: 24399786.
New Medicare Benefits Schedule (MBS) Items for multiparametric magnetic resonance imaging (mpMRI) of the prostate. [Last updated: 20/06/2018.] Available from URL: www.msac.gov.au/internet/msac/publishing.nsf/…/1397-FinalPSD-accessible.docx
Einspieler I, Rauscher I, Düwel C et al. Detection efficacy of hybrid 68Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by phoenix criteria. J Nucl Med 2017; 58: 1081-7.
Afshar-Oromieh A, Avtzi E, Giesel FL et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209.
Calais J, Fendler WP, Eiber M et al. Impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 2018; 59: 434-41.
Udovicich C, Perera M, Hofman MS et al. 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: current state and future trends. Prostate Int 2017; 5: 125-9.
Lieng H, Kneebone A, Hayden AJ et al. Radiotherapy for node-positive prostate cancer: 2019 recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiother Oncol 2019; 140: 68-75.
Corfield J, Perera M, Bolton D, Lawrentschuk N. 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 2018; 36: 519-27.
Uprimny C, Kroiss AS, Decristoforo C et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44: 941-9.
Sachpekidis C, Kopka K, Eder M et al. 68Ga-PSMA-11 dynamic PET/CT imaging in primary prostate cancer. Clin Nucl Med 2016; 41: e473-9.
Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-16.
Berger I, Annabattula C, Lewis J et al. 68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prostatic Dis 2018; 21: 204-11.
Zamboglou C, Drendel V, Jilg CA et al. Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics 2017; 7: 228-37.
Scheltema MJ, Chang JI, Stricker PD et al. Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI. BJU Int 2019; 124(Suppl 1): 42-9.
Weinreb JC, Barentsz JO, Choyke PL et al. PI-RADS prostate imaging - reporting and data system: 2015, Version 2. Eur Urol 2016; 69: 16-40.
Grubmüller B, Baltzer P, Hartenbach S et al. PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. Clin Cancer Res 2018; 24: 6300-7.
Roach PJ, Francis R, Emmett L et al. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an australian prospective multicenter study. J Nucl Med 2018; 59: 82-8.
Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010; 106: 1607-11.
Battaglia A, De Meerleer G, Tosco L et al. Novel insights into the management of oligometastatic prostate cancer: a comprehensive review. Eur Urol Oncol 2019; 2: 174-88.
Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-37.
Amin A, Blazevski A, Thompson J et al. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU Int 2020; 125: 515-24.